OD-OS Achieves Revocation of Iridex MicroPulse Patent

OD-OS has achieved the revocation of the MicroPulse Patent (Patent no EP1856774) by Iridex Corporation in oral proceedings at the European Patent office held last Friday in Munich, Germany according to an OD-OS news release.

With its successful opposition, OD-OS has cleared the path to manufacture and market its Navilas Laser System with microsecond pulsing technology. Navilas features computer-assisted laser delivery and digital documentation, thus making subthreshold treatment of retinal diseases more predictable, and easier to reproduce in standard clinical practice.

The technology of using laser pulses down to 25 microseconds for retinal care has been introduced and marketed by Iridex as MicroPulse laser. MicroPulse is a trademark of Iridex Corporation.

“We fully respect the effort Iridex Corperation has put into the clinical development how tissue-sparing, shorter laser pulses can be effective for retinal treatments,” Winfried Teiwes, Managing Director, OD-OS, said in the company news release. “With Navilas, we are providing a contact free, easy to use and transparent delivery technique of these laser pulses, which allows standardized treatment protocols. We will work with Navilas users to make microsecond pulse treatment a non-contact, non-damaging but long-lasting treatment in clinical practice, and a viable addition to often chronical injections.”